Inhibition of thrombin generation in recalcified plasma

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 8, 2007, Pages 751-760

  Stief, Thomas W ^a,b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Aprotinin; Argatroban; Corn trypsin inhibitor; Danaparoid; Fondaparinux; Heparin; Hirudin

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; ARGATROBAN; ARGININE; CALCIUM CHLORIDE; CITRIC ACID; DANAPAROID; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; POLYSTYRENE; THROMBIN; TRYPSIN INHIBITOR;

ARTICLE; BLOOD CLOTTING; CALCIFICATION; CONTROLLED STUDY; HEMOSTASIS; HUMAN; IC 50; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

ANTICOAGULANTS; APROTININ; BLOOD COAGULATION TESTS; CHONDROITIN SULFATES; DERMATAN SULFATE; HEPARIN; HEPARITIN SULFATE; HIRUDINS; HUMANS; PIPECOLIC ACIDS; PLANT PROTEINS; PLASMA; POLYSACCHARIDES; THROMBIN;

EID: 35848935826     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282f09e6f     Document Type: Article

References (42)

1. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic - thrombotic system. Thromb Haemost 2006; 96:553-561.
2. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int 2007; 11:178-189.
3. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007; 21:113-126.
4. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998; 82:3L-10L.
5. Stief TW. The efficiency of anti-activated factor X and anti-activated factor II anticoagulants. Blood Coagul Fibrinolysis 2007; 18:265-269.
6. Stief TW. Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation. Clin Appl Thromb Hemost 2006; 12:37-61.
7. Stief TW. Inhibition of thrombin in plasma by heparin or arginine. Clin Appl Thromb Hemost 2007; 13:146-153.
8. Stief TW. Thrombin generation by hemolysis. Blood Coagul Fibrinolysis 2007; 18:61-66.
9. 20 test: the corrected chi-square comparison against the control-mean. Clin Appl Thromb Hemost 2007; 13:73-100.
10. Ghebrehiwet B, CebadaMora C, Tantral L, Jesty J, Peerschke EI. gC1qR/ p33 serves as a molecular bridge between the complement and contact activation systems and is an important catalyst in inflammation. Adv Exp Med Biol 2006; 586:95-105.
11. Abe H, Fujihara M, Azuma H, Ikeda H, Ikebuchi K, Takeoka S, et al. Interaction of hemoglobin vesicles, a cellular-type artificial oxygen carrier, with human plasma: effects on coagulation, kallikrein-kinin, and complement systems. Artif Cells Blood Substit Immobil Biotechnol 2006; 34:1-10.
12. Tang J, Yu CL, Williams SR, Springman E, Jeffery D, Sprengeler PA, et al. Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein. J Biol Chem 2005; 280:41077-41089.
13. Governa M, Amati M, Fenoglio I, Valentino M, Coloccini S, Bolognini L, et al. Variability of biological effects of silicas: different degrees of activation of the fifth component of complement by amorphous silicas. Toxicol Appl Pharmacol 2005; 208:68-77.
14. Yahyapour N, Eriksson C, Malmberg P, Nygren H. Thrombin, kallikrein and complement C5b-9 adsorption on hydrophilic and hydrophobic titanium and glass after short time exposure to whole blood. Biomaterials 2004; 25:3171-3176.
15. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99:3585-3596.
16. Governa M, Fenoglio I, Amati M, Valentino M, Bolognini L, Coloccini S, et al. Cleavage of the fifth component of human complement and release of a split product with C5a-like activity by crystalline silica through free radical generation and kallikrein activation. Toxicol Appl Pharmacol 2002; 179:129-136.
17. Yarovaya GA, Blokhina TB, Neshkova EA. Contact system. New concepts on activation mechanisms and bioregulatory functions. Biochemistry 2002; 67:13-24.
18. Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V. Activation of complement and contact system in Alzheimer's disease. Mech Ageing Dev 2001; 122:1971-1983.
19. Kaplan AP, Joseph K, Shibayama Y, Reddigari S, Ghebrehiwet B. Activation of the plasma kinin forming cascade along cell surfaces. Int Arch Allergy Immunol 2001; 124:339-342.
20. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995; 91:28-36.
21. Wachtfogel YT, DeLa Cadena RA, Colman RW. Structural biology, cellular interactions and pathophysiology of the contact system. Thromb Res 1993; 72:1-21.
22. Bengtsson A. Cascade system activation in shock. Acta Anaesthesiol Scand Suppl 1993; 98:7-10.
23. Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman RW, et al. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 1992; 140:897-906.
24. Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77:2660-2667.
25. Arvidsson S, Askendal A, Tengvall P. Blood plasma contact activation on silicon, titanium and aluminium. Biomaterials 2007; 28:1346-1354.
26. Wuillemin WA, Fijnvandraat K, Derkx BH, Peters M, Vreede W, ten Cate H, Hack CE. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1995; 74:1436-1441.
27. Sundaram S, Lim F, Cooper SL, Colman RW. Role of leucocytes in coagulation induced by artificial surfaces: investigation of expression of Mac-1, granulocyte elastase release and leucocyte adhesion on modified polyurethanes. Biomaterials 1996; 17:1041-1047.
28. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol 2007; 28:184-192.
29. Stief TW. The anticoagulant capacity of plasmatic unfractionated heparin decreases at 23 degrees C. Blood Coagul Fibrinolysis 2007; 18:209-212.
30. Koster A, Huebler S, Merkle F, Hentschel T, Grundel M, Krabatsch T, et al. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. Anesth Analg 2004; 98:285-290.
31. Hayashi J, Salomon DR, Hugli TE. Elevated kallikrein activity in plasma from stable liver transplant recipients. Int Immunopharmacol 2002; 2:1667-1680.
32. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001; 71:745-754.
33. Sonntag J, Dahnert I, Stiller B, Hetzer R, Lange PE. Complement and contact activation during cardiovascular operations in infants. Ann Thorac Surg 1998; 65:525-531.
34. Nielsen EW, Johansen HT, Hogasen K, Wuillemin W, Hack CE, Mollnes TE. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 1996; 44:185-192.
35. Seghaye MC, Duchateau J, Grabitz RG, Jablonka K, Wenzl T, Marcus C, et al. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg 1996; 61:1205-1211.
36. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharmacol 1996; 27 (Suppl 1):S50-S57.
37. Segal HC, Hunt BJ, Cottam S, Beard C, Francis JL, Potter D, Tan KC. Changes in the contact system during orthotopic liver transplantation with and without aprotinin. Transplantation 1995; 59:366-370.
38. Heller W, Wendel HP. Clivarin and other LMWHs in an ex vivo cardiopulmonary bypass model. Studies on contact activation. Blood Coagul Fibrinolysis 1993; 4 (Suppl 1):S45-S54.
39. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993; 55:1033-1041.
40. Stief TW. Inhibition of intrinsic thrombin generation. Drug Target Insights 2006; 2:6-11.
41. Stief TW. Quantification of thrombin generation by trypsin. J Med Biol Sci (Sci J Int) 2007; 1/2:1-8.
42. Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost 2006; 12:267-276.